These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 7537900

  • 1. The use of chemotherapy as palliative treatment for patients with advanced ovarian cancer.
    Markman M.
    Semin Oncol; 1995 Apr; 22(2 Suppl 3):25-9. PubMed ID: 7537900
    [Abstract] [Full Text] [Related]

  • 2. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Apr; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 3. New options for the treatment of advanced ovarian cancer.
    Dunton CJ.
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [Abstract] [Full Text] [Related]

  • 4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 5. Salvage chemotherapy for epithelial ovarian carcinoma.
    Christian MC, Trimble EL.
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S143-50. PubMed ID: 7835799
    [Abstract] [Full Text] [Related]

  • 6. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A.
    Anticancer Res; 2007 Dec; 27(3B):1645-51. PubMed ID: 17595790
    [Abstract] [Full Text] [Related]

  • 7. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY, Barnes MN, Niwas S, Robertson MW, Alvarez R, Austin JM, Kilgore LC, Partridge EE.
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [Abstract] [Full Text] [Related]

  • 8. Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
    Markman M.
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):88-9. PubMed ID: 7597438
    [Abstract] [Full Text] [Related]

  • 9. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T, Vance R, Puneky L, Khansur T.
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [Abstract] [Full Text] [Related]

  • 10. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A, Lück HJ, Meerpohl HG.
    Zentralbl Gynakol; 1997 Dec; 119(7):299-323. PubMed ID: 9340970
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of etoposide, carboplatin, and ifosfamide as salvage therapy in advanced ovarian carcinoma.
    Beddoe AM, Dottino PR, Cohen CJ.
    Mt Sinai J Med; 1993 Sep; 60(4):311-6. PubMed ID: 8232377
    [Abstract] [Full Text] [Related]

  • 12. Treatment options in patients with recurrent ovarian cancer.
    Gadducci A, Conte P, Cianci C, Negri S, Genazzani AR.
    Anticancer Res; 2001 Sep; 21(5):3557-64. PubMed ID: 11848523
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapy of advanced ovarian cancer.
    Martoni A, Cacciari N, Angelelli B, Zamagni C, Pannuti F.
    Front Biosci; 1997 Mar 15; 2():g20-6. PubMed ID: 9159262
    [Abstract] [Full Text] [Related]

  • 14. Gynecological malignancies.
    Schaebler DL, Schilder RJ, Young RC.
    Cancer Chemother Biol Response Modif; 1996 Mar 15; 16():564-91. PubMed ID: 8639401
    [Abstract] [Full Text] [Related]

  • 15. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
    Muggia FM.
    Semin Oncol; 2004 Dec 15; 31(6 Suppl 14):17-24. PubMed ID: 15726530
    [Abstract] [Full Text] [Related]

  • 16. Chemotherapy for advanced ovarian cancer: overview of randomized trials.
    Thigpen JT.
    Semin Oncol; 2000 Jun 15; 27(3 Suppl 7):11-6. PubMed ID: 10952121
    [Abstract] [Full Text] [Related]

  • 17. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
    Alici S, Saip P, Eralp Y, Aydiner A, Topuz E.
    Am J Clin Oncol; 2003 Aug 15; 26(4):358-62. PubMed ID: 12902885
    [Abstract] [Full Text] [Related]

  • 18. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.
    Chiara S, Tognoni A, Pastrone I, Tomasello L, Brema F, Di Costanzo G, Folco U, Pronzato P, GONO (Italian Gruppo Oncologico del Nord-Ovest).
    Gynecol Oncol; 2004 May 15; 93(2):474-8. PubMed ID: 15099965
    [Abstract] [Full Text] [Related]

  • 19. Secondary therapy for epithelial ovarian cancer--1994.
    Sutton GP.
    Semin Oncol; 1994 Aug 15; 21(4 Suppl 7):32-6. PubMed ID: 8091239
    [Abstract] [Full Text] [Related]

  • 20. Ifosfamide in the treatment of ovarian cancer.
    Markman M.
    Semin Oncol; 1996 Jun 15; 23(3 Suppl 6):47-9. PubMed ID: 8677449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.